Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its product ALTO-100 during the Class Period from February 2, 2024, to October 22, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit is on behalf of purchasers of Alto's common stock during the IPO and the specified Class Period [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by September 19, 2025, to represent other class members [3]. Group 2: Allegations Against Alto Neuroscience - Defendants allegedly made false statements about ALTO-100's effectiveness in treating major depressive disorder, overstating its clinical and commercial prospects [5]. - The lawsuit claims that Alto's business and financial prospects were also overstated due to these misleading statements [5]. - Investors reportedly suffered damages when the true details about the product and the company's prospects became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its leadership in securities class action settlements and has a history of successful outcomes for its clients [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Alto Neuroscience, Inc. due to allegations of misleading statements regarding the effectiveness of its drug ALTO-100 for treating major depressive disorder (MDD) [2][4]. Group 1: Legal Investigation and Class Action - Investors who suffered losses exceeding $50,000 in Alto are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - A federal securities class action has been filed against Alto, with a deadline of September 19, 2025, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [7]. Group 2: Allegations Against Alto - The complaint alleges that Alto and its executives violated federal securities laws by making false statements and failing to disclose critical information about ALTO-100's effectiveness [4]. - Specifically, it is claimed that ALTO-100 was less effective in treating MDD than represented, leading to overstated clinical and commercial prospects [4]. Group 3: Stock Performance Impact - Following the announcement of ALTO-100's Phase 2b trial results, which did not meet its primary endpoint, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 on October 23, 2024 [5]. - Analysts reacted by adjusting their price targets, with Jeffries reducing its target for Alto from $33 to $17, citing concerns over the company's biomarker approach [6].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug ALTO-100 during the class period from February 2, 2024, to October 22, 2024 [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Alto securities during the specified class period [2]. - Investors have until September 19, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. - The complaint alleges that the Offering Documents for the IPO were negligently prepared and that key information about ALTO-100's effectiveness was not disclosed [3]. Group 2: Impact on Stock Price - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for treating Major Depressive Disorder (MDD), leading to a significant stock price drop [4]. - Following the announcement, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [4]. Group 3: Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [5][8].

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired: (a) Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024 (the “IPO” or “Offering”); and/or (b) Alto securities between February 2, ...

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or “the Company”) (NYSE: ANRO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired (1) Alto ...

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its product ALTO-100 and its business prospects [1][5]. Group 1: Lawsuit Details - The lawsuit is on behalf of purchasers of Alto common stock during the IPO on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by September 19, 2025, to represent other class members [3]. Group 2: Allegations Against Alto Neuroscience - Defendants allegedly made materially false and misleading statements about Alto's business and operations [5]. - Specific claims include that ALTO-100 was less effective in treating major depressive disorder than represented, leading to overstated clinical and commercial prospects [5]. - The lawsuit asserts that when the true information became public, investors suffered damages [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top for securities class action settlements and has recovered hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Group 1 - A shareholder class action lawsuit has been filed against Alto Neuroscience, Inc. alleging that the company made materially false and/or misleading statements regarding its business and operations [1] - The lawsuit claims that ALTO-100 was less effective in treating Major Depressive Disorder (MDD) than previously communicated to investors, leading to overstated clinical, regulatory, and commercial prospects [1] - As a result of these allegations, the lawsuit asserts that Alto's overall business and financial prospects were also overstated [1] Group 2 - Investors who purchased shares of Alto between February 2, 2024, and October 22, 2024, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline for investors to request to be appointed as lead plaintiff in the case is September 19, 2025 [3] - Holzer & Holzer, LLC is a law firm specializing in representing shareholders and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Alto Neuroscience, Inc. (“Alto Neuroscience” or the “Company”) (NYSE: ANRO) (i) between February 2, 2024 and October 22, 2024, inclusive (the “Class Period”); and/or (ii) pursuant and/or traceable to Alto Neuroscience’s registrat ...

NEW YORK, July 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the O ...

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Group 1: Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company based in the U.S. with a product pipeline that includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of its IPO [1]. - The IPO occurred on or about February 2, 2024, and the class period for the lawsuit extends from this date to October 22, 2024 [1]. Group 2: Allegations and Misleading Information - The lawsuit alleges that the Offering Documents related to the IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness [2]. - Specifically, it is claimed that ALTO-100 was less effective in treating MDD than represented, leading to overstated clinical, regulatory, and commercial prospects, which in turn inflated Alto's business and financial outlook [2]. Group 3: Impact of Clinical Trial Results - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo [3]. - Following this announcement, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [3]. Group 4: Legal Proceedings - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4]. - Participation in the case is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4].